Emine Hidayet
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Emine Hidayet has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Emin Kaya
Division of Hematology, Department of Internal Medicine, Faculty of Medicine, İnönü University, 44280 Malatya, Türkiye
6 shared publications - Ilhami Berber
Division of Hematology, Department of Internal Medicine, Faculty of Medicine, İnönü University, 44280 Malatya, Türkiye
6 shared publications - Mehmet Ali Erkurt
Division of Hematology, Department of Internal Medicine, Faculty of Medicine, İnönü University, 44280 Malatya, Türkiye
6 shared publications - Ahmet Kaya
Inonu University, Turgut Ozal Medical Center, Department of Hematology, Malatya, Turkey
5 shared publications - Ahmet Sarıcı
Division of Hematology, Department of Internal Medicine, Faculty of Medicine, İnönü University, 44280 Malatya, Türkiye
5 shared publications - İrFan Kuku
Division of Hematology, Department of Internal Medicine, Faculty of Medicine, İnönü University, 44280 Malatya, Türkiye
5 shared publications
Latest Publications
- 18 May 2026
- Published by MediHealth Academy in Journal of Current Hematology & Oncology Research
- Vol. 4 (2) , 47-52
CD34+ cell dose as a determinant of engraftment kinetics after autologous stem cell transplantation in lymphoma
Aims: Lymphomas are heterogeneous hematologic malignancies for which autologous hematopoietic stem cell transplantation (ASCT) remains an important therapeutic option in relapsed or refractory disease. In addition to patient- and disease-related factors, graft-related parameters—particularly the infused CD34+ cell dose—play a critical role in hematopoietic recovery after ASCT. This study aimed to evaluate post-transplant engraftment and long-term survival outcomes in patients with Hodgkin and non-Hodgkin lymphoma according to infused CD34+ cell dose. Methods: Demographic characteristics, primary diagnosis, infused CD34+ cell dose, neutrophil and platelet engraftment times, 1-year mortality, and 5-year survival were retrospectively obtained from hospital electronic records. Patients were stratified into two groups based on infused CD34+ cell dose: 2–5 × 106/kg and >5 × 106/kg. Engraftment times and survival outcomes were compared between groups. Results: A total of 165 patients were included (2–5 × 106/kg, n = 67; >5 × 106/kg, n = 98). Baseline characteristics, including age, sex, and lymphoma subtype, were comparable between groups. Neutrophil and platelet engraftment times were significantly longer in the 2–5 × 106/kg group than in the >5 × 106/kg group (p < 0.001 for both). In the overall cohort, CD34+ cell dose was negatively correlated with engraftment times. However, no significant differences were observed in 1-year mortality or 5-year survival between groups. Conclusion: Adequate CD34+ cell dosing is essential for rapid hematopoietic recovery after ASCT, whereas higher doses do not appear to confer additional long-term survival benefit.
- 18 May 2026
- Published by MediHealth Academy in Journal of Current Hematology & Oncology Research
- Vol. 4 (2) , 47-52
CD34+ cell dose as a determinant of engraftment kinetics after autologous stem cell transplantation in lymphoma
Aims: Lymphomas are heterogeneous hematologic malignancies for which autologous hematopoietic stem cell transplantation (ASCT) remains an important therapeutic option in relapsed or refractory disease. In addition to patient- and disease-related factors, graft-related parameters—particularly the infused CD34+ cell dose—play a critical role in hematopoietic recovery after ASCT. This study aimed to evaluate post-transplant engraftment and long-term survival outcomes in patients with Hodgkin and non-Hodgkin lymphoma according to infused CD34+ cell dose. Methods: Demographic characteristics, primary diagnosis, infused CD34+ cell dose, neutrophil and platelet engraftment times, 1-year mortality, and 5-year survival were retrospectively obtained from hospital electronic records. Patients were stratified into two groups based on infused CD34+ cell dose: 2–5 × 106/kg and >5 × 106/kg. Engraftment times and survival outcomes were compared between groups. Results: A total of 165 patients were included (2–5 × 106/kg, n = 67; >5 × 106/kg, n = 98). Baseline characteristics, including age, sex, and lymphoma subtype, were comparable between groups. Neutrophil and platelet engraftment times were significantly longer in the 2–5 × 106/kg group than in the >5 × 106/kg group (p < 0.001 for both). In the overall cohort, CD34+ cell dose was negatively correlated with engraftment times. However, no significant differences were observed in 1-year mortality or 5-year survival between groups. Conclusion: Adequate CD34+ cell dosing is essential for rapid hematopoietic recovery after ASCT, whereas higher doses do not appear to confer additional long-term survival benefit.
- 27 June 2025
- Published by Elsevier in Transplantation Proceedings
- Vol. 57 (6) , 1133-1142
Cytomegalovirus Infection Risk Factors in Allogeneic Hematopoietic Stem Cell Transplantation Can Defibrotide Be a Risk Factor?
- 27 June 2025
- Published by Elsevier in Transplantation Proceedings
- Vol. 57 (6) , 1133-1142
Cytomegalovirus Infection Risk Factors in Allogeneic Hematopoietic Stem Cell Transplantation Can Defibrotide Be a Risk Factor?
- 8 July 2023
- Published by Wiley in Journal of Clinical Apheresis
- Vol. 38 (5) , 602-610
Effect of extracorporeal photopheresis on survival in acute graft versus host disease
Background: Extracorporeal photopheresis (ECP) is the main non‐pharmacological approach accompanying systemic medical treatments in steroid‐resistant acute or chronic graft versus host disease. The study aimed to examine the effect of ECP on survival in acute graft versus host disease (aGVHD).Methods: A total of 35 patients who were followed up in the adult hematology clinic of İnönü University Turgut Özal Medical Center for aGVHD were included in the study. Stem cell transplantation and ECP application parameters that may affect the survival of the patients were examined.Results: In aGVHD using ECP, the degree of involvement affects survival. Involvements with a clinical and laboratory score (Glucksberg system) of 2 and above significantly reduced survival. The duration of ECP use is associated with survival. Especially, 45 days and longer use increases survival (hazard ratio, P‐value <.05). The duration of steroid use was found to be effective in survival in aGVHD (P < .001). ECP administration day (P = .003), duration of steroid use (P < .001), duration of ECP use (P = .001), and grade of aGVHD (P < .001) affect survival.Conclusion: ECP use is effective in survival in patients with aGVHD score ≥2. In patients with aGVHD, especially the use of 45 days and longer has a positive effect on survival. The duration of steroid use is associated with survival in aGVHD.
- 8 July 2023
- Published by Wiley in Journal of Clinical Apheresis
- Vol. 38 (5) , 602-610
Effect of extracorporeal photopheresis on survival in acute graft versus host disease
Background: Extracorporeal photopheresis (ECP) is the main non‐pharmacological approach accompanying systemic medical treatments in steroid‐resistant acute or chronic graft versus host disease. The study aimed to examine the effect of ECP on survival in acute graft versus host disease (aGVHD).Methods: A total of 35 patients who were followed up in the adult hematology clinic of İnönü University Turgut Özal Medical Center for aGVHD were included in the study. Stem cell transplantation and ECP application parameters that may affect the survival of the patients were examined.Results: In aGVHD using ECP, the degree of involvement affects survival. Involvements with a clinical and laboratory score (Glucksberg system) of 2 and above significantly reduced survival. The duration of ECP use is associated with survival. Especially, 45 days and longer use increases survival (hazard ratio, P‐value <.05). The duration of steroid use was found to be effective in survival in aGVHD (P < .001). ECP administration day (P = .003), duration of steroid use (P < .001), duration of ECP use (P = .001), and grade of aGVHD (P < .001) affect survival.Conclusion: ECP use is effective in survival in patients with aGVHD score ≥2. In patients with aGVHD, especially the use of 45 days and longer has a positive effect on survival. The duration of steroid use is associated with survival in aGVHD.
- Open Access
- 26 February 2023
- Published by MediHealth Academy in Journal of Current Hematology & Oncology Research
- Vol. 1 (1) , 1-4
Effect of tyrosine kinase inhibitor and conventional chemotherapy on COVID 19 antibody level in hematological patients
Aims: In this study, we aim to discover if there is a difference between COVID 19 antibody level in hematological patients taking conventional chemotherapy and tyrosin kinase inhibitors. Methods: COVİD 19 IgG levels were measured using the QuantiCOR anti-SARS-CoV-2 IgG ELISA test kit on 74 patients who received chemotherapy and used tyrosine kinase inhibitors in the adult hematology clinic of Turgut Özal Medical Center between May 2019 and January 2022. Age, height, weight, badimeks index of the patients were measured, the doses and durations of vaccine use, the time between the first vaccine and the second vaccine, how long after the first vaccine antibodies were checked, and vaccine-related side effects were recorded. Collected data Statistical analysis was performed using Python 3.9 and IBM SPSS Statistics for Windows version 26.0 (New York; USA). Results: Antibody levels of the patients were significantly higher in the healthy control group than in the groups that received chemotherapy and tyrosine kinase inhibitors. Antibody levels of female patients in the control group were higher than male patients. Antibody levels of the patient groups receiving chemotherapy and tyrosine kinase inhibitor were not found to differ between the two groups. When the patients receiving B lymphocyte suppressing chemotherapy in the chemotherapy group were compared with the control group, antibody levels were found to be higher in the control group. Conclusion: COVID 19 vaccination in hematological cancers did not produce adequate antibody response, especially in patients receiving chemotherapy or tyrosine kinase inhibitors.
- 26 February 2023
- Published by MediHealth Academy in Journal of Current Hematology & Oncology Research
- Vol. 1 (1) , 1-4
Open AccessEffect of tyrosine kinase inhibitor and conventional chemotherapy on COVID 19 antibody level in hematological patients
Aims: In this study, we aim to discover if there is a difference between COVID 19 antibody level in hematological patients taking conventional chemotherapy and tyrosin kinase inhibitors. Methods: COVİD 19 IgG levels were measured using the QuantiCOR anti-SARS-CoV-2 IgG ELISA test kit on 74 patients who received chemotherapy and used tyrosine kinase inhibitors in the adult hematology clinic of Turgut Özal Medical Center between May 2019 and January 2022. Age, height, weight, badimeks index of the patients were measured, the doses and durations of vaccine use, the time between the first vaccine and the second vaccine, how long after the first vaccine antibodies were checked, and vaccine-related side effects were recorded. Collected data Statistical analysis was performed using Python 3.9 and IBM SPSS Statistics for Windows version 26.0 (New York; USA). Results: Antibody levels of the patients were significantly higher in the healthy control group than in the groups that received chemotherapy and tyrosine kinase inhibitors. Antibody levels of female patients in the control group were higher than male patients. Antibody levels of the patient groups receiving chemotherapy and tyrosine kinase inhibitor were not found to differ between the two groups. When the patients receiving B lymphocyte suppressing chemotherapy in the chemotherapy group were compared with the control group, antibody levels were found to be higher in the control group. Conclusion: COVID 19 vaccination in hematological cancers did not produce adequate antibody response, especially in patients receiving chemotherapy or tyrosine kinase inhibitors.
- Open Access
- 31 January 2023
- Published by Marmara University in Marmara Medical Journal
- Vol. 36 (1) , 65-71
The effect of preemptive use of plerixafor on stem cell mobilization in patients with lymphoma and multiple myeloma
Objective: The aim of this study is to investigate the effect of the preemptive use of plerixafor in patients with lymphoma and multiple myeloma which was administered as a preemptive single dose to the patients who were determined to have a CD34+ cell count of <15/ μL in the peripheral blood (PB) on the 4th day of mobilization. Patients and Methods: Thirty-five patients who were administered plerixafor on the 4th day after granulocyte colony-stimulating factor (G-CSF) alone for stem cell mobilization between January 2020 and November 2021 were included. CD34+ stem cell counts in PB before and after plerixafor, the amount of CD34+ stem cells collected, and the outcome of transplantation was examined. Results: The median CD34+ cell count in PB on the 4th day was 5.2/μL (0.1-13.4), which was determined to increase 206.6-fold (31.57- 49347) to 924.80 /μL (295.00-5056) following the administration of plerixafor on the 5th day (Z=-5.160; r= – 872.2; p<0.0001). The number of apheresis sessions was 1 in all patients. The median collected CD34+ cell count was 5.90x106/kg (2.70x106-14.4x106). Conclusion: The use of preemptive plerixafor shows that it is an effective mobilization method by increasing the rate of stem cell collection at an effective dose and reducing the mobilization time/apheresis sessions.
- 31 January 2023
- Published by Marmara University in Marmara Medical Journal
- Vol. 36 (1) , 65-71
Open AccessThe effect of preemptive use of plerixafor on stem cell mobilization in patients with lymphoma and multiple myeloma
Objective: The aim of this study is to investigate the effect of the preemptive use of plerixafor in patients with lymphoma and multiple myeloma which was administered as a preemptive single dose to the patients who were determined to have a CD34+ cell count of <15/ μL in the peripheral blood (PB) on the 4th day of mobilization. Patients and Methods: Thirty-five patients who were administered plerixafor on the 4th day after granulocyte colony-stimulating factor (G-CSF) alone for stem cell mobilization between January 2020 and November 2021 were included. CD34+ stem cell counts in PB before and after plerixafor, the amount of CD34+ stem cells collected, and the outcome of transplantation was examined. Results: The median CD34+ cell count in PB on the 4th day was 5.2/μL (0.1-13.4), which was determined to increase 206.6-fold (31.57- 49347) to 924.80 /μL (295.00-5056) following the administration of plerixafor on the 5th day (Z=-5.160; r= – 872.2; p<0.0001). The number of apheresis sessions was 1 in all patients. The median collected CD34+ cell count was 5.90x106/kg (2.70x106-14.4x106). Conclusion: The use of preemptive plerixafor shows that it is an effective mobilization method by increasing the rate of stem cell collection at an effective dose and reducing the mobilization time/apheresis sessions.